Jamie Farrell

Jamie Farrell

Auto-generated profile, based on publicly available information

Jamie Farrell

Clinical Epidemiology Unit, Division of Community Health and Humanities, Faculty of Medicine, Memorial University, St. John’s, Newfoundland and Labrador, Canada

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2021 in Clinical Epidemiology
Verified
Journal Article
Open access
PDF file
MAMichael Asamoah-Boaheng
Michael Asamoah-Boaheng
KBKwadwo Osei Bonsu
Kwadwo Osei Bonsu
JFJamie Farrell
Jamie Farrell
AOAlwell Oyet
Alwell Oyet
WMWilliam K Midodzi
William K Midodzi
Background: Limited studies have systematically reviewed the literature to identify and compare the various database methods and optimal thresholds for measuring medication adherence specific to adolescents and adults with asthma. In the present study, we aim to identify the methods and optimal thresholds for measuring medication adherence in population-based pharmacy databases. Methods: We searched PubMed, Embase, International Pharmaceutical Abstracts (IPA), Web of Science, Google Scholar, and grey literature from January 1, 1998, to March 16, 2021. Two independent reviewers screened the studies, extracted the data, and assessed the quality of the studies. A quantitative knowledge synthesis was employed. Results: Thirty-eight (38) retrospective cohort studies were eligible. This review identified 20 methods for measuring medication adherence in adolescent and adult asthma administrative health records. Two measures namely the medication possession ratio (MPR) and proportion of days covered (PDC) were commonly reported in 87% of the literature included in this study. From the meta-analysis, asthma patients who achieved adherence threshold of “ 0.75– 1.00” [OR: 0.56, 95% CI: 0.41 to 0.77] and “> 0.5” [OR: 0.71, 95% CI: 0.54 to 0.94] were less likely to experience asthma exacerbation. Conclusion: Despite their limitations, the PDC and the MPR still remain the most common measures for assessing adherence in asthma pharmacy claim databases. The evidence synthesis showed that an adherence threshold of at least 0.75 is optimal for classifying adherent and non-adherent asthma patients.

10 June 2019 in JMIR mHealth and uHealth
Verified
Journal Article
Open access
meshari alwashmimeshari alwashmi
meshari alwashmi
BFBeverly FitzPatrick
Beverly FitzPatrick
EDErin Davis
Erin Davis
JGJM Gamble
JM Gamble
JFJamie Farrell
Jamie Farrell
JHJohn Hawboldt
John Hawboldt
Journal of Medical Internet Research - International Scientific Journal for Medical Research, Information and Communication on the Internet #Preprint #PeerReviewMe: Warning: This is a unreviewed preprint. Readers are warned that the document has not been peer-reviewed by expert/patient reviewers or an academic editor, may contain misleading claims, and is likely to undergo changes before final publication, if accepted, or may have been rejected/withdrawn. Readers with interest and expertise are encouraged to sign up as peer-reviewer, if the paper is within an open peer-review period. Please cite this preprint only for review purposes or for grant applications and CVs (if you are the author). Background: Using a Mobile Health (mHealth) intervention, consisting of a smartphone and compatible medical device, has the potential to enhance Chronic Obstructive Pulmonary Disease (COPD) treatment outcomes while mitigating health care costs. The purpose of this study is to understand the perceptions of health care providers (HCPs) regarding the use of mHealth in COPD management. Objective: To explore the potential facilitators and barriers among HCPs regarding the use of mHealth interventions for COPD management. Methods: This is a qualitative study. Semi-structured individual interviews were conducted with 30 HCPs, including nurses, pharmacists, and physicians who work directly with COPD patients. A flexible prompts guide was used to facilitate discussions. Topics included: demographics, mHealth usage, perceptions towards challenges of mHealth adoption, factors facilitating mHealth adoption, and preferences regarding features of the mHealth intervention for COPD management. Interviews were conversational in nature and items were not asked verbatim or in the order presented. The interviews were transcribed verbatim and compared against the digital recordings to ensure the accuracy of the content. After creating a codebook for analysis, two researchers independently coded the remaining interview data using pattern coding. They discussed commonalities and differences in coding until consensus was reached. Results: A total of 30 nurses, physicians, and pharmacists participated. The main facilitators to mHealth adoption are possible health benefits for patients, ease of use, educating patients and their HCPs, credibility, and reducing the cost to the healthcare system. Alternatively, the barriers adoption are technical issues, privacy and confidentiality issues, lack of awareness, potential limited uptake from the elderly, potential limited connection between patients and HCPs, and finances. Conclusions: It is important to understand the perceptions of HCPs regarding adoption of innovative mHealth interventions for COPD management. This study identifies some potential facilitators and barriers that may inform the successful development and implementation of mHealth interventions for COPD management.

23 July 2020 in JMIR mHealth and uHealth
Verified
Journal Article
Open access
meshari alwashmimeshari alwashmi
meshari alwashmi
BFBeverly FitzPatrick
Beverly FitzPatrick
JFJamie Farrell
Jamie Farrell
JGJM Gamble
JM Gamble
EDErin Davis
Erin Davis
JHJohn Hawboldt
John Hawboldt
Background: Using a mobile health (mHealth) intervention consisting of a smartphone and compatible medical device has the potential to enhance chronic obstructive pulmonary disease (COPD) treatment outcomes while mitigating health care costs. Objective: This study aims to describe the demographics, use, and access to smartphones of patients with COPD. It also aims to explore and develop an understanding of potential facilitators and barriers that might influence patients using mHealth interventions for COPD management. Methods: This was an explanatory, sequential mixed methods study. Patients who attended respirology clinics completed a questionnaire on technology access and use. We conducted semistructured individual interviews with the patients. Interview topics included the following: demographics, mHealth use, perceptions toward challenges of mHealth adoption, factors facilitating mHealth adoption, and preferences regarding features of mHealth interventions for COPD management. Results: A total of 100 adults completed the survey but 22 participants were excluded because they were not diagnosed with COPD. Of these, 10 patients with COPD participated in the interview. The quantitative component revealed that many patients with COPD owned a mobile phone, but only about one-fourth of the participants (18/77, 23%) owned a smartphone. The likelihood of owning a smartphone was not associated with age, sex, marital status, or geographical location, but patients with high educational status were more likely to own a smartphone. The qualitative component found that patients with COPD, in general, had a positive attitude toward mHealth adoption for COPD management, but several facilitators and barriers were identified. The main facilitators of mHealth adoption are possible health benefits for patients, ease of use, educating patients, and credibility. Alternatively, the barriers to adoption are technical issues, lack of awareness, potential limited uptake from older adults, privacy and confidentiality issues, finances, and lack of interest in mHealth Conclusions: It is important to understand the perceptions of patients with COPD regarding the adoption of innovative mHealth interventions for COPD management. This study identifies some potential facilitators and barriers that may inform the successful development and implementation of mHealth interventions for COPD management.

1 May 2022 in International Journal of Chronic Obstructive Pulmonary Disease
Verified
Journal Article
Open access
PDF file
JAJoseph Emil Amegadzie
Joseph Emil Amegadzie
JGJM Gamble
JM Gamble
JFJamie Farrell
Jamie Farrell
ZGZhiwei Gao
Zhiwei Gao
Purpose: Despite ample evidence underpinning the efficacy of β2-agonists in asthma and chronic obstructive pulmonary disease (COPD), the occurrence of β1- and β2-adrenoceptors in the heart suggests that β2-agonists may have deleterious cardiac effects. We investigated the association between new users of long-or short-acting β2-agonists (LABA or SABA) or ICS (inhaled corticosteroids)/LABA and major adverse cardiovascular events (MACE). Methods: A nested case–control analysis was conducted using the UK Clinical Practice Research Datalink of patients with asthma, COPD or asthma–COPD overlap with initial treatment of LABA, SABA, ICS/LABA, ICS, long-or short-acting muscarinic antagonist (LAMA or SAMA) between 01 January 1998 and 31 July 2018. The primary outcome was MACE, defined as the first occurrence of stroke, heart failure, myocardial infarction, arrhythmia, or cardiovascular death. Each case was matched with up to 10 controls on age, sex, date of cohort-entry, and duration of follow-up. The risk of MACE associated with β2-agonists was estimated using conditional logistic regression after controlling for potential confounders. Results: The cohort included 180,567 new users of β2-agonists, ICS, SAMA, or LAMA. Among asthmatics, β2-agonists were not associated with the risk of MACE (SABA vs ICS: HR 1.29 [0.96– 1.73]; ICS/LABA vs ICS, HR 0.75 [0.33– 1.73]). In contrast, among COPD patients, LABA (HR, 2.38 [1.04– 5.47]), SABA (HR, 2.02 [1.13– 3.59]) and ICS/LABA (HR, 2.08 [1.04– 4.16]) users had an increased risk of MACE compared with SAMA users. Among patients with asthma–COPD overlap, SABA (HR, 2.57 [1.26– 5.24]) was associated with an increased risk of MACE compared with ICS. Conclusion: In conclusion, initiation of LABA, SABA, or ICS/LABA in COPD or SABA in asthma–COPD overlap is associated with increased risk of MACE. No associations were observed among patients with asthma.

3 September 2021 in COPD: Journal of Chronic Obstructive Pulmonary Disease
Verified
Journal Article
Open access
UOUgochukwu Odimba
Ugochukwu Odimba
ASAmbikaipakn Senthilselvan
Ambikaipakn Senthilselvan
JFJamie Farrell
Jamie Farrell
ZGZhiwei Gao
Zhiwei Gao
Asthma-COPD overlap (ACO) is a newly identified phenotype of chronic obstructive airway diseases with shared asthma and COPD features. Patients with ACO are poorly defined, and some evidence suggests that they have worse health outcomes and greater disease burden than patients with COPD or asthma. Generally, there is no evidence-based and universal definition for ACO; several consensus documents have provided various descriptions of the phenotype. In addition, the mechanisms underlying the development of ACO are not fully understood. Whether ACO is a distinct clinical entity with its particular discrete genetic determinant different from asthma and COPD alone or an intermediate phenotype with overlapping genetic markers within asthma and COPD spectrum of obstructive airway disease remains unproven. This review summarizes the current knowledge of the genetic risk factors, characteristics, and prognosis of ACO.

1 September 2020 in International Journal of Chronic Obstructive Pulmonary Disease
Verified
Journal Article
Open access
PDF file
JAJoseph Emil Amegadzie
Joseph Emil Amegadzie
JGJM Gamble
JM Gamble
JFJamie Farrell
Jamie Farrell
ZGZhiwei Gao
Zhiwei Gao
Purpose: Gender differences in the incidence, susceptibility and severity of many obstructive airway diseases (OADs) have been well recognized. However, gender differences in the inhaled pharmacotherapy profile are not well characterized. Methods: We conducted a retrospective cohort study to investigate gender differences in new-users of inhaled corticosteroids (ICS), short-or long-acting beta2-agonist (SABA or LABA), ICS/LABA, short-or long-acting muscarinic antagonist (SAMA or LAMA) among patients with asthma, COPD or asthma-COPD overlap (ACO). We used Clinical Practice Research Datalink to identify OAD patients, 18 years and older, who were new-users (1-year washout period) from 01-January-1998 to 31-July-2018. Multivariable logistic regression was used to examine gender differences in each of the inhaled pharmacotherapies after controlling for potential confounders. Results: A total of 242,079 new-users (asthma: 84.93%; COPD: 10.19%; ACO: 4.88%) of inhaled pharmacotherapies were identified. The multivariable analyses showed that males with COPD were more likely to be a new user of a LABA (odds ratio [OR] 1.29; 95% confidence interval [CI], 1.12– 1.49), LAMA (OR 1.21; 95% CI 1.10– 1.33), SAMA (OR 1.11; 95% CI 1.01– 1.21) and less likely to be a new user of a SABA (OR 0.84; 95% CI, 0.80– 0.89) compared to females. Similar patterns were also observed for patients with ACO; males were more likely to be prescribed with LABA (OR 1.26; 95% CI 1.03– 1.55), LAMA (OR 1.28; 95% CI 1.11– 1.48), SAMA (OR 1.28; 95% CI 1.11– 1.48), and less likely to be a new user of a SABA (OR 0.89; 95% CI, 0.82– 0.96). Also, males with asthma were more likely to be a new-user of ICS/LABA (OR 1.15; 95% CI, 1.08– 1.23) and less likely to start an ICS (OR 0.97; 95% CI, 0.95– 0.99) in comparison with females. Conclusion: Our study showed significant gender differences in new-users of inhaled pharmacotherapies among OAD patients. Adjusting for proxies of disease severity, calendar year, smoking and socioeconomic status did not change the association by gender.